盐酸Ilginatinib（盐酸NS-018）是一款高效口服JAK2小分子抑制剂，通过与ATP竞争结合发挥作用，半数抑制浓度（IC50）为0.72nM。该化合物对JAK2具有高选择性，相较于JAK1（IC5033nM）、JAK3（IC5039nM）和Tyk2（IC5022nM）的选择性达22-54倍，整体比其他JAK家族激酶高30-50倍。此外，它还能显著抑制Src家族激酶中的SRC和FYN，可作为骨髓增生性肿瘤相关研究的工具化合物。

[1] Nakaya Y, Shide K, Niwa T, Homan J, Sugahara S, Horio T, Kuramoto K, Kotera T, Shibayama H, Hori K, Naito H, Shimoda K. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011 Jul;1(7):e29. doi: 10.1038/bcj.2011.29. Epub 2011 Jul 22. PMID: 22829185; PMCID: PMC3255248.[2]Kuroda J, Kodama A, Chinen Y, Shimura Y, Mizutani S, Nagoshi H, Kobayashi T, Matsumoto Y, Nakaya Y, Tamura A, Kobayashi Y, Naito H, Taniwaki M. NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients. Leuk Res. 2014 May;38(5):619-24. doi: 10.1016/j.leukres.2014.03.001. Epub 2014 Mar 11. PMID: 24679585.